Symbols / CTKB Stock $4.62 +1.32% Cytek Biosciences, Inc.

Healthcare • Medical Devices • United States • NMS
CTKB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Dr. Wenbin Jiang Ph.D.
Exch · Country NMS · United States
Market Cap 596.64M
Enterprise Value 356.12M
Income -66.54M
Sales 201.49M
FCF (ttm) 4.33M
Book/sh 2.66
Cash/sh 2.03
Employees 702
Insider 10d —
IPO Jul 23, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 77.00
PEG —
P/S 2.96
P/B 1.74
P/C —
EV/EBITDA -10.86
EV/Sales 1.77
Quick Ratio 4.29
Current Ratio 5.04
Debt/Eq 6.95
LT Debt/Eq —
EPS (ttm) -0.52
EPS next Y 0.06
EPS Growth —
Revenue Growth 8.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-02-26
ROA -5.25%
ROE -18.05%
ROIC —
Gross Margin 51.84%
Oper. Margin -9.00%
Profit Margin -33.02%
Shs Outstand 129.14M
Shs Float 96.92M
Insider Own 8.34%
Instit Own 65.99%
Short Float 7.95%
Short Ratio 12.98
Short Interest 8.10M
52W High 6.18
vs 52W High -25.24%
52W Low 2.37
vs 52W Low 94.94%
Beta 1.28
Impl. Vol. 2.68%
Rel Volume 0.57
Avg Volume 733.58K
Volume 415.41K
Target (mean) $6.00
Tgt Median $5.75
Tgt Low $5.00
Tgt High $7.50
# Analysts 4
Recom Buy
Prev Close $4.56
Price $4.62
Change 1.32%
About

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools. Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.00
Mean price target
2. Current target
$4.62
Latest analyst target
3. DCF / Fair value
$0.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.62
Low
$5.00
High
$7.50
Mean
$6.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-01-08 main TD Cowen Buy → Buy $5
2025-11-11 main Piper Sandler Overweight → Overweight $8
2025-05-28 main Morgan Stanley Equal-Weight → Equal-Weight $7
2025-05-12 main Goldman Sachs Sell → Sell $3
2025-03-19 reit Stephens & Co. Overweight → Overweight $6
2025-03-04 main Piper Sandler Overweight → Overweight $8
2024-11-11 main Piper Sandler Overweight → Overweight $9
2024-08-13 main Piper Sandler Overweight → Overweight $8
2024-05-13 main Piper Sandler Overweight → Overweight $9
2024-03-06 main Piper Sandler Overweight → Overweight $10
2024-02-29 main Goldman Sachs Buy → Buy $10
2023-12-14 init Stephens & Co. — → Overweight $9
2023-11-09 main Morgan Stanley Equal-Weight → Equal-Weight $7
2023-10-24 main Morgan Stanley Equal-Weight → Equal-Weight $8
2023-10-16 main Piper Sandler Overweight → Overweight $10
2023-07-19 init Raymond James — → Market Perform —
2023-05-11 main Morgan Stanley Equal-Weight → Equal-Weight $13
2023-05-10 main Goldman Sachs — → Buy $12
2023-03-07 main Piper Sandler — → Overweight $15
2023-03-02 main Morgan Stanley — → Equal-Weight $14
News
RSS: Latest CTKB news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-13 YAN MING Chief Technology Officer — 1,176,000 $0.00 $0
2026-03-10 BUSQUE PHILIPPE PH.D. Officer — 9,828 — —
2026-03-10 CHIN RICHARD M.D. PH.D. Director — 6,107 — —
2026-03-10 HOLDER MICHAEL Director — 2,908 — —
2026-03-10 BARNETT VALERIE Officer — 29,722 — —
2026-03-10 JIANG WENBIN Chief Executive Officer — 83,844 — —
2026-03-10 YAN MING Chief Technology Officer — 25,400 — —
2026-03-10 MCCOMBE WILLIAM D. Chief Financial Officer — 23,721 — —
2026-02-18 BARNETT VALERIE Officer — 1,346 — —
2026-02-18 JIANG WENBIN Chief Executive Officer — 4,514 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
201.49
+0.52%
200.45
+3.85%
193.01
+17.67%
164.04
Operating Revenue
201.49
+0.52%
200.45
+3.85%
193.01
+17.67%
164.04
Cost Of Revenue
97.03
+8.60%
89.35
+6.89%
83.59
+32.55%
63.06
Reconciled Cost Of Revenue
97.03
+8.60%
89.35
+6.89%
83.59
+32.55%
63.06
Gross Profit
104.46
-5.98%
111.11
+1.54%
109.43
+8.37%
100.97
Operating Expense
144.84
+10.04%
131.63
-4.11%
137.27
+33.56%
102.78
Research And Development
36.47
-7.45%
39.40
-10.76%
44.15
+26.66%
34.86
Selling General And Administration
108.38
+17.51%
92.23
-0.96%
93.12
+37.10%
67.92
Selling And Marketing Expense
49.44
+0.66%
49.11
-0.07%
49.15
+47.90%
33.23
General And Administrative Expense
58.94
+36.70%
43.11
-1.95%
43.97
+26.76%
34.69
Other Gand A
58.94
+36.70%
43.11
-1.95%
43.97
+26.76%
34.69
Total Expenses
241.88
+9.46%
220.98
+0.05%
220.86
+33.18%
165.84
Operating Income
-40.38
-96.77%
-20.52
+26.30%
-27.84
-1443.51%
-1.80
Total Operating Income As Reported
-40.38
-96.77%
-20.52
+26.30%
-27.84
-1443.51%
-1.80
EBITDA
-17.39
-73.35%
-10.03
-127.61%
-4.41
-146.44%
9.49
Normalized EBITDA
-17.39
-73.35%
-10.03
-127.61%
-4.41
-146.44%
9.49
Reconciled Depreciation
11.97
+14.16%
10.49
+13.65%
9.23
+63.10%
5.66
EBIT
-29.37
-43.09%
-20.52
-50.48%
-13.64
-455.80%
3.83
Net Income
-66.54
-1005.30%
-6.02
+50.44%
-12.15
-571.58%
2.58
Pretax Income
-29.84
-423.53%
-5.70
+63.72%
-15.71
-1346.75%
1.26
Net Non Operating Interest Income Expense
1.74
-83.19%
10.36
+138.60%
4.34
+112.22%
2.05
Interest Expense Non Operating
0.47
—
2.07
-19.51%
2.57
Net Interest Income
1.74
-83.19%
10.36
+138.60%
4.34
+112.22%
2.05
Interest Expense
0.47
—
2.07
-19.51%
2.57
Interest Income Non Operating
2.22
-78.61%
10.36
+61.55%
6.41
+38.84%
4.62
Interest Income
2.22
-78.61%
10.36
+61.55%
6.41
+38.84%
4.62
Other Income Expense
8.80
+97.20%
4.46
-42.74%
7.79
+665.62%
1.02
Other Non Operating Income Expenses
8.80
+97.20%
4.46
-42.74%
7.79
+665.62%
1.02
Tax Provision
36.70
+11368.13%
0.32
+108.99%
-3.56
-190.93%
-1.22
Tax Rate For Calcs
0.00
+0.00%
0.00
-7.36%
0.00
+7.95%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-66.54
-1005.30%
-6.02
+50.44%
-12.15
-589.05%
2.48
Net Income From Continuing Operation Net Minority Interest
-66.54
-1005.30%
-6.02
+50.44%
-12.15
-571.58%
2.58
Net Income From Continuing And Discontinued Operation
-66.54
-1005.30%
-6.02
+50.44%
-12.15
-571.58%
2.58
Net Income Continuous Operations
-66.54
-1005.30%
-6.02
+50.44%
-12.15
-589.05%
2.48
Minority Interests
0.00
0.00
0.00
-100.00%
0.09
Normalized Income
-66.54
-1005.30%
-6.02
+50.44%
-12.15
-571.58%
2.58
Net Income Common Stockholders
-66.54
-1005.30%
-6.02
+50.44%
-12.15
-571.58%
2.58
Otherunder Preferred Stock Dividend
—
—
0.00
0.00
Diluted EPS
-0.52
-940.00%
-0.05
+42.31%
-0.09
-533.35%
0.02
Basic EPS
-0.52
-940.00%
-0.05
+42.31%
-0.09
-533.35%
0.02
Basic Average Shares
127.75
-2.19%
130.61
-0.08%
130.71
-2.82%
134.51
Diluted Average Shares
127.75
-2.19%
130.61
-0.08%
130.71
-5.66%
138.56
Diluted NI Availto Com Stockholders
-66.54
-1005.30%
-6.02
+50.44%
-12.15
-571.58%
2.58
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
461.54
-7.60%
499.50
+1.02%
494.46
-4.82%
519.48
Current Assets
392.00
-1.12%
396.45
+1.12%
392.06
-13.65%
454.02
Cash Cash Equivalents And Short Term Investments
261.53
-5.88%
277.86
+5.89%
262.41
-23.08%
341.15
Cash And Cash Equivalents
90.85
-7.97%
98.72
-40.99%
167.30
-43.59%
296.60
Cash Equivalents
61.87
-6.91%
66.47
-54.13%
144.89
-16.36%
173.23
Cash Financial
28.98
-10.13%
32.25
+43.93%
22.41
-81.84%
123.37
Other Short Term Investments
170.68
-4.73%
179.15
+88.35%
95.11
+113.50%
44.55
Receivables
72.13
+19.05%
60.59
+7.96%
56.12
+10.31%
50.88
Accounts Receivable
62.51
+3.17%
60.59
+8.33%
55.93
+14.46%
48.86
Gross Accounts Receivable
—
60.90
+8.17%
56.30
+14.98%
48.97
Allowance For Doubtful Accounts Receivable
—
-0.31
+16.67%
-0.37
-264.71%
-0.10
Other Receivables
4.21
—
—
—
Taxes Receivable
5.41
0.00
-100.00%
0.19
-90.45%
2.01
Inventory
48.43
+10.33%
43.89
-27.90%
60.88
+26.42%
48.15
Raw Materials
20.44
-9.43%
22.57
-36.81%
35.72
+32.66%
26.93
Work In Process
16.53
+154.79%
6.49
-37.94%
10.45
+113.48%
4.90
Finished Goods
11.46
-22.78%
14.83
+0.88%
14.71
-9.96%
16.33
Prepaid Assets
6.93
-42.84%
12.13
+20.21%
10.09
+41.21%
7.15
Restricted Cash
0.00
-100.00%
0.03
-91.24%
0.33
-88.58%
2.90
Other Current Assets
2.98
+53.22%
1.94
-12.87%
2.23
-41.25%
3.80
Total Non Current Assets
69.55
-32.51%
103.05
+0.64%
102.40
+56.44%
65.46
Net PPE
29.32
+4.24%
28.13
-3.86%
29.26
+6.14%
27.57
Gross PPE
41.46
+12.52%
36.84
+4.74%
35.18
+14.50%
30.72
Accumulated Depreciation
-12.13
-39.25%
-8.71
-47.20%
-5.92
-87.40%
-3.16
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
7.92
+2.05%
7.76
+1.44%
7.65
+37.82%
5.55
Machinery Furniture Equipment
5.41
+46.47%
3.69
+11.20%
3.32
+16.44%
2.85
Construction In Progress
1.42
+296.92%
0.36
+39.45%
0.26
+43.82%
0.18
Other Properties
23.19
+6.35%
21.81
+7.29%
20.32
+8.92%
18.66
Leases
3.52
+9.12%
3.22
-11.01%
3.62
+4.08%
3.48
Goodwill And Other Intangible Assets
33.52
-8.90%
36.79
-6.31%
39.27
+171.27%
14.47
Goodwill
16.70
+0.20%
16.66
+2.97%
16.18
+59.53%
10.14
Other Intangible Assets
16.82
-16.43%
20.13
-12.81%
23.08
+432.99%
4.33
Non Current Deferred Assets
0.00
-100.00%
33.37
+9.47%
30.49
+49.02%
20.46
Non Current Deferred Taxes Assets
0.00
-100.00%
33.37
+9.47%
30.49
+49.02%
20.46
Other Non Current Assets
6.70
+40.87%
4.76
+40.59%
3.38
+14.47%
2.96
Total Liabilities Net Minority Interest
119.80
+15.46%
103.76
+2.34%
101.39
+7.95%
93.93
Current Liabilities
77.80
+14.99%
67.66
+20.34%
56.23
+14.65%
49.04
Payables And Accrued Expenses
20.92
+32.68%
15.77
+27.36%
12.38
-9.56%
13.69
Payables
12.69
+39.67%
9.09
+49.18%
6.09
-5.87%
6.47
Accounts Payable
6.41
+15.93%
5.53
+82.35%
3.03
-36.90%
4.80
Current Accrued Expenses
8.22
+23.17%
6.68
+6.22%
6.29
-12.86%
7.21
Pensionand Other Post Retirement Benefit Plans Current
15.19
+2.89%
14.77
+7.40%
13.75
-1.17%
13.91
Total Tax Payable
6.28
+76.54%
3.56
+16.31%
3.06
+83.56%
1.67
Income Tax Payable
3.07
+102.31%
1.52
+16.89%
1.30
+427.24%
0.25
Current Debt And Capital Lease Obligation
9.18
+9.06%
8.41
+179.63%
3.01
-14.30%
3.51
Current Debt
6.30
+35.17%
4.66
+724.42%
0.56
-2.59%
0.58
Other Current Borrowings
6.30
+35.17%
4.66
+724.42%
0.56
-2.59%
0.58
Current Capital Lease Obligation
2.88
-23.32%
3.76
+53.68%
2.44
-16.62%
2.93
Current Deferred Liabilities
29.57
+11.13%
26.61
+10.26%
24.13
+65.97%
14.54
Current Deferred Revenue
29.57
+11.13%
26.61
+10.26%
24.13
+65.97%
14.54
Other Current Liabilities
2.95
+39.75%
2.11
-28.71%
2.96
-12.77%
3.39
Total Non Current Liabilities Net Minority Interest
42.00
+16.34%
36.10
-20.07%
45.17
+0.62%
44.89
Long Term Debt And Capital Lease Obligation
14.57
+69.34%
8.60
-22.69%
11.13
-23.70%
14.58
Long Term Debt
0.53
-50.00%
1.05
-36.29%
1.65
-27.43%
2.27
Long Term Capital Lease Obligation
14.04
+85.94%
7.55
-20.33%
9.48
-23.01%
12.31
Non Current Deferred Liabilities
18.34
+13.92%
16.10
+6.38%
15.13
+15.30%
13.12
Non Current Deferred Revenue
18.34
+13.92%
16.10
+6.38%
15.13
+15.30%
13.12
Other Non Current Liabilities
9.09
-20.24%
11.40
-39.71%
18.91
+10.04%
17.18
Preferred Securities Outside Stock Equity
—
—
—
—
Stockholders Equity
341.74
-13.64%
395.74
+0.68%
393.06
-7.58%
425.30
Common Stock Equity
341.74
-13.64%
395.74
+0.68%
393.06
-7.58%
425.30
Capital Stock
0.13
+0.00%
0.13
-1.53%
0.13
-2.96%
0.14
Common Stock
0.13
+0.00%
0.13
-1.53%
0.13
-2.96%
0.14
Share Issued
128.55
-0.51%
129.21
-1.15%
130.71
-3.44%
135.37
Ordinary Shares Number
128.55
-0.51%
129.21
-1.15%
130.71
-3.44%
135.37
Additional Paid In Capital
441.11
+2.39%
430.79
+1.75%
423.39
-4.40%
442.89
Retained Earnings
-101.74
-189.04%
-35.20
-20.64%
-29.18
-71.33%
-17.03
Gains Losses Not Affecting Retained Earnings
2.24
+13906.25%
0.02
+101.25%
-1.27
-82.93%
-0.70
Minority Interest
0.00
0.00
0.00
-100.00%
0.25
Other Equity Adjustments
2.24
+13906.25%
0.02
+101.25%
-1.27
-82.93%
-0.70
Total Equity Gross Minority Interest
341.74
-13.64%
395.74
+0.68%
393.06
-7.63%
425.55
Total Capitalization
342.26
-13.74%
396.79
+0.53%
394.71
-7.68%
427.57
Working Capital
314.19
-4.44%
328.78
-2.10%
335.83
-17.07%
404.98
Invested Capital
348.56
-13.17%
401.44
+1.56%
395.28
-7.68%
428.15
Total Debt
23.74
+39.53%
17.02
+20.37%
14.14
-21.87%
18.09
Capital Lease Obligations
16.92
+49.65%
11.31
-5.16%
11.92
-21.78%
15.24
Net Tangible Assets
308.22
-14.13%
358.95
+1.46%
353.80
-13.88%
410.82
Tangible Book Value
308.22
-14.13%
358.95
+1.46%
353.80
-13.88%
410.82
Line Of Credit
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-4.69
-118.46%
25.38
+380.57%
5.28
+143.18%
-12.23
Cash Flow From Continuing Operating Activities
-4.69
-118.46%
25.38
+380.57%
5.28
+143.18%
-12.23
Net Income From Continuing Operations
-66.54
-1005.30%
-6.02
+50.44%
-12.15
-589.05%
2.48
Depreciation Amortization Depletion
11.97
+14.16%
10.49
+13.65%
9.23
+63.10%
5.66
Depreciation
11.97
+14.16%
10.49
+13.65%
9.23
+63.10%
5.66
Depreciation And Amortization
11.97
+14.16%
10.49
+13.65%
9.23
+63.10%
5.66
Other Non Cash Items
-0.33
+95.44%
-7.19
-556.06%
1.58
-27.59%
2.18
Stock Based Compensation
24.59
-8.43%
26.85
+21.77%
22.05
+32.86%
16.59
Provisionand Write Offof Assets
2.12
+33.75%
1.58
-8.92%
1.74
+102.45%
0.86
Deferred Tax
33.56
+1262.75%
-2.89
0.00
0.00
Deferred Income Tax
33.56
+1262.75%
-2.89
0.00
0.00
Operating Gains Losses
-5.26
-1.98%
-5.16
+22.51%
-6.65
-8541.56%
-0.08
Gain Loss On Investment Securities
-5.67
-8.87%
-5.21
+21.77%
-6.66
-8550.65%
-0.08
Gain Loss On Sale Of PPE
0.41
+654.55%
0.06
+685.71%
0.01
0.00
Change In Working Capital
-4.79
-162.15%
7.71
+173.39%
-10.51
+73.68%
-39.93
Change In Receivables
0.37
+106.78%
-5.43
+25.97%
-7.33
+62.86%
-19.74
Changes In Account Receivables
0.37
+106.78%
-5.43
+25.97%
-7.33
+62.86%
-19.74
Change In Inventory
-5.24
-135.54%
14.76
+244.26%
4.29
+124.28%
-17.65
Change In Prepaid Assets
-2.66
+5.38%
-2.81
+70.48%
-9.52
+50.86%
-19.36
Change In Payables And Accrued Expense
4.42
+150.31%
1.76
+267.30%
-1.05
-111.31%
9.33
Change In Accrued Expense
3.97
+585.92%
-0.82
-212.07%
0.73
-90.24%
7.47
Change In Payable
0.45
-82.65%
2.58
+244.73%
-1.78
-195.81%
1.86
Change In Account Payable
0.45
-82.65%
2.58
+244.73%
-1.78
-195.81%
1.86
Change In Other Working Capital
3.60
-3.64%
3.74
-42.68%
6.52
-30.72%
9.41
Change In Other Current Liabilities
-5.28
-22.57%
-4.31
-26.19%
-3.41
-78.50%
-1.91
Investing Cash Flow
10.12
+112.19%
-82.97
+11.63%
-93.89
-67.94%
-55.91
Cash Flow From Continuing Investing Activities
10.12
+112.19%
-82.97
+11.63%
-93.89
-67.94%
-55.91
Net PPE Purchase And Sale
-3.83
-18.38%
-3.24
+30.36%
-4.65
+52.32%
-9.75
Purchase Of PPE
-4.08
-15.86%
-3.52
+24.16%
-4.65
+52.32%
-9.75
Sale Of PPE
0.25
-12.50%
0.29
0.00
0.00
Capital Expenditure
-4.19
-12.36%
-3.73
+22.75%
-4.83
+51.08%
-9.87
Net Investment Purchase And Sale
14.06
+117.78%
-79.06
-79.95%
-43.94
+4.57%
-46.04
Purchase Of Investment
-278.15
-1.49%
-274.06
-55.77%
-175.94
-282.13%
-46.04
Sale Of Investment
292.21
+49.85%
195.00
+47.73%
132.00
0.00
Net Business Purchase And Sale
0.00
+100.00%
-0.47
+98.96%
-45.13
0.00
Purchase Of Business
0.00
+100.00%
-0.47
+98.96%
-45.13
0.00
Net Intangibles Purchase And Sale
-0.11
+48.04%
-0.20
-13.97%
-0.18
-49.17%
-0.12
Purchase Of Intangibles
-0.11
+48.04%
-0.20
-13.97%
-0.18
-49.17%
-0.12
Net Other Investing Changes
-0.00
—
—
—
Financing Cash Flow
-13.43
+15.11%
-15.82
+62.16%
-41.81
-858.43%
5.51
Cash Flow From Continuing Financing Activities
-13.43
+15.10%
-15.82
+62.16%
-41.81
-858.43%
5.51
Net Issuance Payments Of Debt
0.84
-76.90%
3.62
+741.42%
-0.56
-119.26%
2.93
Issuance Of Debt
5.58
+33.51%
4.18
0.00
-100.00%
2.98
Repayment Of Debt
-4.75
-751.89%
-0.56
+1.42%
-0.56
-1030.00%
-0.05
Long Term Debt Issuance
—
4.18
0.00
-100.00%
2.98
Long Term Debt Payments
-4.75
-751.89%
-0.56
+1.42%
-0.56
-1030.00%
-0.05
Net Long Term Debt Issuance
-4.75
-751.89%
-0.56
+1.42%
-0.56
-119.26%
2.93
Short Term Debt Issuance
5.58
+33.51%
4.18
0.00
—
Net Short Term Debt Issuance
5.58
+33.51%
4.18
0.00
—
Net Common Stock Issuance
-15.07
+30.25%
-21.61
+51.05%
-44.15
0.00
Common Stock Payments
-15.07
+30.25%
-21.61
+51.05%
-44.15
0.00
Repurchase Of Capital Stock
-15.07
+30.25%
-21.61
+51.05%
-44.15
0.00
Proceeds From Stock Option Exercised
1.47
-45.79%
2.72
-18.18%
3.32
+19.15%
2.79
Net Other Financing Charges
-0.67
-20.76%
-0.55
-32.22%
-0.42
-100.48%
-0.21
Changes In Cash
-8.00
+89.10%
-73.42
+43.71%
-130.43
-108.26%
-62.63
Effect Of Exchange Rate Changes
0.11
-97.59%
4.53
+413.63%
-1.45
+41.99%
-2.49
Beginning Cash Position
98.75
-41.09%
167.63
-44.03%
299.50
-17.86%
364.62
End Cash Position
90.85
-7.99%
98.75
-41.09%
167.63
-44.03%
299.50
Free Cash Flow
-8.88
-141.00%
21.65
+4668.72%
0.45
+102.05%
-22.10
Income Tax Paid Supplemental Data
2.16
-43.60%
3.83
-27.84%
5.30
-48.94%
10.39
Amortization Of Securities
—
—
—
-0.08
Common Stock Issuance
—
—
0.00
0.00
Earnings Losses From Equity Investments
—
—
0.00
0.00
Issuance Of Capital Stock
—
—
0.00
0.00
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
Sale Of Business
—
—
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category